Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 459-467 , May 2006

In vitro and in vivo evaluation of novel ligands for radioimmunotherapy

  • Hyun-Soon Chong

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    • Chemistry Division, Department of Biological, Chemical, and Physical Sciences, Illinois Institute of Technology, Chicago, IL 60616, USA
    • Corresponding Author InformationCorresponding author. Chemistry Division, Biological, Chemical, and Physical Science Department, Illinois Institute of Technology, Chicago, IL 60616, USA. Tel.: +1 312 567 3235; fax: +1 312 567 3494.
    • ,
  • Diane E. Milenic

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    • ,
  • Kayhan Garmestani

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    • ,
  • Erik D. Brady

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    • ,
  • Hans Arora

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    • ,
  • Candice Pfiester

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    • ,
  • Martin W. Brechbiel

      Affiliations

    • Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA

Received 22 December 2005 ,Revised 30 January 2006 ,Accepted 7 March 2006.

References 

  1. Knox SJ, Meredith RF. Clinical radioimmunotherapy. Semin Radiat Oncol. 2000;10:73–93
  2. Schubiger PA, Alberto R, Smith A. Vehicles, chelators, and radionuclides: choosing the “building blocks” of an effective therapeutic radioimmunoconjugate. Bioconjug Chem. 1996;7:165–179
  3. Srivastava SC. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm. 1996;11:43–50
  4. Juweid M, Neumann RD, Paik CH. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52:5144–5153
  5. Jurcic JG, McDevitt MR, Sgouros G, Ballangrud AM, Finn RD, Ma D, et al. Phase 1 trial of targeted alpha particle therapy for myeloid leukemia with 213-Bi-HuM195(anti-CD33). Proc Am Soc Clin Oncol. 1999;18:7–12
  6. Couturier O, Faivre-Chauvet A, Filippovich IV, Thedrez P, Sai-Maurel C, Bardies M, et al. Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin Cancer Res. 1999;5(10 Suppl):3165s–3170s
  7. Hassfjell S, Brechbiel MW. The development of the α-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides for therapeutic applications. Chem Rev. 2001;101:2019–2036
  8. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid and study of its yttrium(III) complex. J Am Chem Soc. 1988;110:6266–6267
  9. Kumar K, Magerstadt M, Gansow OA. Lead(II) and Bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and tteta. J Chem Soc Chem Commun. 1989;145–146
  10. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221–4226
  11. Kumar K, Chang CA, Tweedle MF. Equilibrium and kinetic studies of lanthanide complexes of macrocyclic polyamino carboxylates. Inorg Chem. 1993;32:587–593
  12. Kodama M, Koike T, Mahatma AB, Kimura E. Thermodynamic and kinetic studies of lanthanide complexes of 1,4,7,10,13-pentaazacyclopentadecane-N,N′,N′′,N′′′,N′′′′-pentaacetic acid and 1,4,7,10,13,16-hexaazacyclcootadecane-N,N′,N′′,N′′′,N′′′′-hexaacetic acid. Inorg Chem. 1991;30:1270–1273
  13. Harrison A, Walker CA, Parker D, Jankowski KJ, Cox JP. The in vivo release of 90-Y from cyclic and acyclic ligand–antibody conjugates. Nucl Med Biol. 1991;18:469–476
  14. Brechbiel MW, Pippin CG, McMurry TJ, Milenic DE, Roselli M, Colcher D, et al. An effective chelating agent for labeling of monoclonal antibody with 212Bi for a-particle mediated radioimmunotherapy. J Chem Soc Chem Commun. 1991;1169–1170
  15. Brechbiel MW, Gansow OA. Backbone-substituted DTPA ligands for 90Y radioimmunotherapy. Bioconjug Chem. 1991;187–194
  16. Ruble G, Wu C, Squire RA, Gansow OA, Strand M. The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. Int J Radiat Oncol Biol Phys. 1996;34:609–616
  17. McMurry TJ, Pippin CG, Wu C, Deal KA, Brechbiel MW, Mirzadeh S, et al. Physical parameters and biological stability of yttrium (III) diethylenetriaminepentaacetic acid derivative conjugates. J Med Chem. 1998;41:3546–3549
  18. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med. 1994;35:882–889
  19. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–470
  20. Scott ME, Schlom J, Siler K, Milenic DE, Eggensperger D, Colcher D, et al. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer. 1994;73(3 Suppl):993–998
  21. Chappell LL, Ma D, Milenic DE, Gramestani K, Venditto V, Beitzel MP, et al. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid for radiolabeling proteins. Nucl Med Biol. 2003;30:581–595
  22. Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, et al. Phase I study of intravenous 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res. 1995;1:1447–1454
  23. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, et al. Intraperitoneal radioimmuno-therapy of ovarian cancer with 177Lμ-CC49: a phase I/II study. Gynecol Oncol. 1997;65:94–101
  24. Chong HS, Garmestani K, Ma D, Milenic DE, Overstreet T, Brechbiel MW. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. J Med Chem. 2002;45:3458–3464
  25. Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol. 2002;29:599–606
  26. Garmestani K, Yao Z, Zhang M, Wong K, Park CW, Pastan I, et al. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl Med Biol. 2001;28:409–418
  27. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203-Pb and 212-Pb. Nucl Med Biol. 2000;27:93–100
  28. Chong HS, Garmestani K, Bryant LH, Brechbiel MW. Synthesis of DTPA analogues derived from piperidine and azepane: potential contrast enhancement agents for magnetic resonance imaging (MRI). J Org Chem. 2001;66:7745–7750
  29. McMurry TJ, Brechbiel MW, Kumar K, Gansow OA. Convenient synthesis of bifunctional tetraaza macrocycles. Bioconjugate Chem. 1992;3:108–117
  30. Chong HS, Garmestani K, Bryant LH, Milenic DE, Overstreet T, Birch N, et al. Synthesis and evaluation of novel macrocyclic and acyclic Ligands as contrast enhancement agents for Magnetic Resonance Imaging (MRI). J Med Chem. 2006;[in Press]
  31. Woods M, Kovacs Z, Kiraly R, Brucher E, Zhang S, Sherry AD. Solution dynamics and stability of lanthanide (III) (S)-2-(p-nitrobenzyl)DOTA complexes. Inorg Chem. 2004;43:2845–2851
  32. Yoo J, Reichert DE, Welch MJ. Comparative in vivo behavior studies of cyclen-based copper-64 complexes: regioselective synthesis, x-ray structure, radiochemistry, log P, and biodistribution. J Med Chem. 2004;47:6625–6637
  33. Li WP, Ma DS, Higginbotham C, Hoffman T, Ketring AR, Cutler CS, et al. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol. 2001;28:145–154

PII: S0969-8051(06)00060-6

doi: 10.1016/j.nucmedbio.2006.03.004

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 459-467 , May 2006

Article Tools

* Image Usage & Resolution